2016
DOI: 10.1080/17425255.2016.1214715
|View full text |Cite
|
Sign up to set email alerts
|

Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies

Abstract: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 This review includes a description of the composition, pharmacokinetics, and mechanisms of action of IVIg. The second part of the paper provides an overview of the immune-mediated polyneuropathies in which IVIg is a first-line therapy, with special focus on the pathomechanism of the disea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 129 publications
0
3
0
Order By: Relevance
“…82, 83 The mechanism of action of IVIG in SCLS is unknown, but we speculate that anti-idiotypic effects on the putative monoclonal autoantibody or neutralization of proinflammatory cytokines by antibodies present in IVIG preparations are two possible mechanisms by which IVIG exerts its prophylactic effects in SCLS. Over the last 8–10 years, monthly prophylaxis with IVIG has become the most commonly applied therapy in the NIH cohort.…”
Section: Prophylactic Therapy and Prognosismentioning
confidence: 96%
“…82, 83 The mechanism of action of IVIG in SCLS is unknown, but we speculate that anti-idiotypic effects on the putative monoclonal autoantibody or neutralization of proinflammatory cytokines by antibodies present in IVIG preparations are two possible mechanisms by which IVIG exerts its prophylactic effects in SCLS. Over the last 8–10 years, monthly prophylaxis with IVIG has become the most commonly applied therapy in the NIH cohort.…”
Section: Prophylactic Therapy and Prognosismentioning
confidence: 96%
“…In particular, intravenous immunoglobulin (IVIG) is used as a replacement therapy in immunodeficient individuals, who are unable to create their own effective immune responses [32]. IVIG can also be used to suppress the pathological immune responses that occur in patients with autoimmunity [33]. IVIG formulations are prepared from the human serum IgG fraction, which is pooled from a minimum of 1000 up to 60,000 donors [34].…”
Section: Pentamer (950 Kda) Serummentioning
confidence: 99%
“…Consequently, a treatment that reduces inflammation may be beneficial in some patients with autism. Intravenous immunoglobulin (IVIG) suppresses systemic inflammation and has long been used in the treatment of inflammatory conditions and autoimmune disease [Dalakas, ; Dezsi, Horvath, & Vecsei, ; Dwyer, ; Emmi & Chiarini, ; Lünemann, Quast, & Dalakas, ; Nikolov, Reisinger, & Schwarz, ; Nimmerjahn & Ravetch, ]. IVIG has been used to treat autism in three phase 1 clinical trials [DelGiudice‐Asch et al, ; Gupta et al, ; Plioplys, ], all with a low‐dose regimen (up to 400 mg/kg) infused at 4‐week intervals and with a relatively short duration of treatment and follow‐up, in a total of 42 children (30 male and 12 female), aged between 3 and 17 years.…”
Section: Introductionmentioning
confidence: 99%